Combined application of biosponges and an antifibrotic agent for the treatment of volumetric muscle loss

• DOI: 10.1152/ajpcell.00092.2023
• Publication Date: 2023-05-15T12:50:39Z
• Authors: Charles West; Connor Tobo; Jeffrey Au; David Johnson; M. Abdul Mottaleb; Jessica Robinson; Saloni Shringarpure; David W. Griggs; Koyal Garg
• Keywords: Vascularity; Muscle tissue

Volumetric muscle loss (VML) causes irrecoverable of mass and strength results in permanent disability. VML injury shows extensive fibrosis, which impedes functional tissue regeneration. Our lab has created a biosponge scaffold composed extracellular matrix (ECM) proteins (i.e., biosponge) that can enhance regeneration function following VML. In this work, potent small molecule inhibitor alpha v-subunit containing integrins known as IDL-2965 was incorporated into the biosponges for localized suppression fibrosis post-VML. demonstrate local delivery via attenuated deposition fibrotic preceded by downregulation profibrotic genes VML-injured muscles. The reduction had no detrimental effects on mass, function, size, or vascularity. Overall, these findings suggest codelivery is safe effective strategy mitigation